Outcomes of EGFR-mutant lung adenocarcinomas (AC) that transform to small cell lung cancer (SCLC)

Authors :: Joel W. Neal
Zofia Piotrowska
Anna Wurtz
Scott N. Gettinger
Heather A. Wakelee
Dora Dias-Santagata
Grainne M. O'Kane
Nicolas Marcoux
Julie R. Brahmer
Salvatore Del Prete
Frances A. Shepherd
Lecia V. Sequist
Anna F. Farago
Mari Mino-Kenudson
Hatim Husain
Helena Alexandra Yu
Philip Bonomi
Tracey L. Evans
Kathryn C. Arbour
Alona Muzikansky
Source :: Journal of Clinical Oncology. 36:8573-8573
Publication Year :: 2018
Publisher :: American Society of Clinical Oncology (ASCO), 2018.
Abstract: 8573Background: 5-10% of EGFR-mutant ACs undergo SCLC/neuroendocrine transformation (SCLC-T) but the clinical course of such pts is poorly characterized. Methods: We identified 50 pts with EGFR-mut...

Subjects :: Cancer Research
Lung
business.industry
Mutant
Clinical course
macromolecular substances
humanities
respiratory tract diseases
Transformation (genetics)
medicine.anatomical_structure
Oncology
otorhinolaryngologic diseases
Cancer research
Medicine
Non small cell
business
neoplasms

Full Text Access

Tools